BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial SiteGlobeNewsWire • 10/25/23
BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 10/12/23
BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate CancerGlobeNewsWire • 10/10/23
BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual FilmGlobeNewsWire • 10/04/23
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 09/05/23
FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 09/04/23
BTAI DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important September 5 Deadline in Securities Class Action – BTAIBusiness Wire • 09/04/23
Important September 5, 2023 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. Investors of Securities Fraud Class Action LawsuitPRNewsWire • 09/03/23
BTAI DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAIPRNewsWire • 09/02/23
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)Business Wire • 09/01/23
SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc.(BTAI) Investors of a Class Action Lawsuit and Upcoming DeadlinePRNewsWire • 08/31/23
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 08/31/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 08/30/23
BTAI Investors Have Opportunity to Lead BioXcel Therapeutics, Inc. Securities Fraud LawsuitPRNewsWire • 08/29/23
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of BioXcel Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 5, 2023 - (NASDAQ: BTAI)PRNewsWire • 08/29/23
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 08/29/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioXcel Therapeutics, Inc. - BTAIPRNewsWire • 08/28/23
SHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc.(BTAI) ShareholdersPRNewsWire • 08/28/23
BTAI CLASS ACTION NOTICE: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. (BTAI) Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the FirmPRNewsWire • 08/26/23
BIOXCEL INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their OptionsPRNewsWire • 08/26/23
BIOXCEL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAIPRNewsWire • 08/26/23
ROSEN, LEADING INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAIPRNewsWire • 08/25/23
